Topics to be addressed (2nd Summer School on Cancer Immunology and Immunotherapy)
- Unrelated stem cell donors for the treatment of haematological malignancies
- Translating old discoveries into tomorrow’s cancer immunotherapy
- T-cell therapy- bringing discovery into the clinic
- TCR structure and function – Clinical trials
- Tumor ablation and immune stimulation
- Targeting xCT in metastatic breast cancer treatment
- NSCLC: updated data with ICIs
- Immunotherapy for the treatment of urothelial cancer
- Biomarkers and immune resistance
- T-cell suppression by cancer cells; off the beaten track
- The role of myeloid-derived suppressor cells in tumor immune evasion
- Modulation of immune responses via PD-L1 targeting
- Immune escape and resistances to immune check point inhibitors
- Ageing and the human immune system in the era of cancer immunotherapy: is it all downhill?
- The Melanoma paradigm for anti-cancer immunotherapy
- Immune biomarkers
- Immunotherapy beyond anti-PD1/PDL1
- The (tremendous) gap between predicted epitopes and those actually recognized by CD8 T cells
- T-cell monitoring for clinical studies: main techniques, pitfalls and quality assurance
- Immune check point inhibitors for the treatment of the head and neck cancer
- Management of immune related toxicity